UK & World News
Breast Cancer: Quitting Drug Costs Lives
More than 400 lives are being lost each year because breast cancer patients fail to take the full course of the drug tamoxifen due to "intolerable" side-effects.
As well as saving lives, £30m each year could be saved by the NHS if patients took their full course of drugs, according to research.
Women who fail to take tamoxifen for the full five years have a higher chance of their cancer coming back and suffering an early death.
Around 13,000 women a year are prescribed a five-year course of tamoxifen, usually after surgery, radiotherapy and any chemotherapy.
Side effects include hot flushes, joint pain, fatigue, weight gain and sweats. Rarer side effects include blood clots.
A new analysis shows patients who do not adhere to their drug regime cost an extra £5,970 on average due to more hospital admissions and needing other medicines.
They also lose an average of 13 months of reasonable quality of life from not taking the once-a-day drug.
Colin McCowan, from the University of Glasgow, and his team analysed prescription records for 1,263 women with breast cancer to see how often they took tamoxifen and for how long.
Women who collected fewer than 80% of their prescriptions were classed as having low adherence to the treatment.
The findings, published in the British Journal of Cancer (BJC), showed 434 lives a year could be saved alongside millions of pounds if women took the drug for five years.
Dr McCowan said: "High adherence to tamoxifen would seem to benefit both the patient and the NHS.
"We do know that side effects of this treatment are an issue and we are currently analysing interviews with women to investigate reasons why they do or don't take their medication and other issues around adherence.
"We hope to use these findings to develop interventions to help women and the NHS to get the most from the life-saving drugs that we already have."
Baroness Delyth Morgan is chief executive of Breast Cancer Campaign, which funded the new study.
She said: "Tamoxifen is one of the most effective treatments for breast cancer when taken as prescribed but sadly some women find it intolerable to take the full five-year course and risk recurrence of their disease.
"This study is a timely reminder that it's so important that women are given support to continue taking their tamoxifen so that they have the best possible chance to outlive breast cancer."
Lesley Smith from Macmillan Cancer Support said problems with side effects were not limited to breast cancer patients.
"Macmillan estimates that at least half a million cancer survivors in the UK currently face disability and poor health due to their illness and its treatment."
In June, it was announced that thousands of women with a family history of breast cancer would be offered tamoxifen to help prevent the disease.
The National Institute for Health and Care Excellence (Nice) said tamoxifen taken daily for five years can cut breast cancer risk by 40% in these women.